Lilly’s Donanemab for Alzheimer – early trial results: “47% of patients “had no clinical progression” on the CDR-SB after one year, which sounds quite interesting, but has to be compared to 29% of the patients in the placebo group who had no progressi

Posted on by

Link. This is at best a mediocre drug for people with Alzheimer’s and probably it’s useless. But maybe there’s a subtype of the dementia where it’s a good drug (albeit with very dangerous side effects).